Pharsight

Radius Health Inc patents expiration

1. Tymlos patents expiration

TYMLOS's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8748382 RADIUS HEALTH INC Method of drug delivery for bone anabolic protein
Oct, 2027

(4 years from now)

US8148333 RADIUS HEALTH INC Stable composition comprising a PTHrP analogue
Nov, 2027

(4 years from now)

US7803770 RADIUS HEALTH INC Method of treating osteoporosis comprising administration of PTHrP analog
Apr, 2031

(7 years from now)

USRE49444 RADIUS HEALTH INC Method of treating osteoporosis comprising administration of PTHrP analog
Apr, 2031

(7 years from now)

US10996208 RADIUS HEALTH INC Abaloparatide formulations and methods of testing, storing, modifying, and using same
Apr, 2038

(14 years from now)

US11255842 RADIUS HEALTH INC Methods for detecting neutralizing antibodies to parathyroid hormone (PTH) and parathyroid hormone-related peptide (PTHRP) analog
Jan, 2040

(16 years from now)

US11680942 RADIUS HEALTH INC Methods for detecting neutralizing antibodies to parathyroid hormone (PTH) and parathyroid hormone-related peptide (PTHrP) analog
Jan, 2040

(16 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M (M) Sep 20, 2024
New Indication (I) Dec 19, 2025

Drugs and Companies using ABALOPARATIDE ingredient

Market Authorisation Date: 28 April, 2017

Treatment: Method of treating postmenopausal women with osteoporosis at high risk for fracture.; Treatment to increase bone density in men with osteoporosis at high risk for fracture; Use for detecting neutraliz...

Dosage: SOLUTION;SUBCUTANEOUS

How can I launch a generic of TYMLOS before it's drug patent expiration?
More Information on Dosage

TYMLOS family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic